The estimated Net Worth of Geoff Race is at least $1.31 Milione dollars as of 28 April 2023. Mr. Race owns over 22,082 units of Minerva Neurosciences Inc stock worth over $137,035 and over the last 10 years he sold NERV stock worth over $321,395. In addition, he makes $850,424 as Executive Vice President e Chief Financial Officer and Chief Business Officer at Minerva Neurosciences Inc.
Sign up
Mr. Race NERV stock SEC Form 4 insiders trading
Geoffrey has made over 5 trades of the Minerva Neurosciences Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 22,082 units of NERV stock worth $85,016 on 28 April 2023.
The largest trade he's ever made was buying 33,333 units of Minerva Neurosciences Inc stock on 30 June 2014 worth over $199,998. On average, Geoffrey trades about 5,659 units every 179 days since 2014. As of 28 April 2023 he still owns at least 51,324 units of Minerva Neurosciences Inc stock.
You can see the complete history of Mr. Race stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Geoffrey Race biography
Geoffrey Race serves as Executive Vice President, Chief Financial Officer and Chief Business Officer of the Company. He has provided services to us since July 2010, first as a consultant and then as an employee beginning in May 2014 as Executive Vice President and Chief Financial Officer. Mr. Race was named our Chief Business Officer in January 2016. Prior to joining us, Mr. Race served as the Chief Executive Officer and acting Chief Financial Officer of Funxional Therapeutics Ltd., a clinical stage pharmaceutical company which was spun out of Cambridge University, UK, from June 2010 to November 2013. Mr. Race is currently a member of the board of directors of Huq Industries Ltd. and F-star Therapeutics Ltd. Mr. Race is a Fellow of the Institute of Chartered Management Accountants and earned his M.B.A. from Durham University Business School (UK).
What is the salary of Geoffrey Race?
As the Executive Vice President e Chief Financial Officer and Chief Business Officer of Minerva Neurosciences Inc, the total compensation of Geoffrey Race at Minerva Neurosciences Inc is $850,424. There are 3 executives at Minerva Neurosciences Inc getting paid more, with Michael Davidson having the highest compensation of $2,842,430.
How old is Geoffrey Race?
Geoffrey Race is 59, he's been the Executive Vice President e Chief Financial Officer and Chief Business Officer of Minerva Neurosciences Inc since 2016. There are 11 older and 7 younger executives at Minerva Neurosciences Inc. The oldest executive at Minerva Neurosciences Inc is David Kupfer, 79, who is the Independent Director.
What's Geoffrey Race's mailing address?
Geoff's mailing address filed with the SEC is C/O MINERVA NEUROSCIENCES, INC., 1500 DISTRICT AVENUE, BURLINGTON, MA, 01803.
Insiders trading at Minerva Neurosciences Inc
Over the last 10 years, insiders at Minerva Neurosciences Inc have traded over $49,043,620 worth of Minerva Neurosciences Inc stock and bought 8,182,692 units worth $47,876,311 . The most active insiders traders include & Johnson Johnson & Johnson..., Venture Associates Iii Ltd ... e Capital Iii Llc Care Capita.... On average, Minerva Neurosciences Inc executives and independent directors trade stock every 46 days with the average trade being worth of $556,476. The most recent stock trade was executed by Remy Luthringer on 28 April 2023, trading 27,394 units of NERV stock currently worth $105,193.
What does Minerva Neurosciences Inc do?
minerva neurosciences, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. its lead product candidate is roluperidone, which is in phase iii clinical trial, a compound for the treatment of schizophrenia. the company is also developing seltorexant that has completed phase iib clinical trial for treating insomnia and major depressive disorders; and min-301, which is in pre-clinical trial, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of parkinson's disease. minerva neurosciences, inc. has a license agreement with mitsubishi tanabe pharma corporation for the development and commercialization of the roluperidone worldwide, excluding asia; and co-development and license agreement with janssen pharmaceutica, n.v. for the development of seltorexant. the company was formerly known as cyrenaic pharmaceuticals, inc. and changed its
What does Minerva Neurosciences Inc's logo look like?
Complete history of Mr. Race stock trades at Minerva Neurosciences Inc
Minerva Neurosciences Inc executives and stock owners
Minerva Neurosciences Inc executives and other stock owners filed with the SEC include:
-
Michael Davidson,
Chief Medical Officer -
Devin Smith,
Senior Vice President, General Counsel -
Remy Luthringer,
Chief Executive Officer and Executive Chairman of the Board of Directors -
Geoffrey Race,
Executive Vice President, Chief Financial Officer and Chief Business Officer -
Dr. Remy Luthringer Ph.D.,
Exec. Chairman & CEO -
Frederick Ahlholm,
Senior Vice President, Chief Accounting Officer -
Dr. Rémy Luthringer,
Exec. Chairman & CEO -
Geoffrey Robin Race F.C.M.A., FCMA, M.B.A., MBA,
Pres -
Dr. Jay B. Saoud Ph.D.,
Consultant -
William Doyle,
Lead Independent Director -
Jan van Heek,
Independent Director -
Jeryl Hilleman,
Independent Director -
Hans Hasler,
Independent Director -
David Kupfer,
Independent Director -
Fouzia Laghrissi-Thode,
Independent Director -
William Boni,
IR Contact Officer -
Jay Saoud,
Senior Vice President, Head of Research and Development -
Joseph Reilly,
Chief Operating Officer, Senior Vice President -
Dr. Ramana Kuchibhatla Ph.D.,
Sr. VP and Head of R&D -
Dr. Michael Davidson M.D.,
Chief Medical Officer -
Joseph Reilly,
Sr. VP & COO -
Frederick W. Ahlholm CPA, CPA,
Chief Financial Officer -
William B. Boni,
VP of Investor Relations & Corp. Communications -
Marc D Beer,
Director -
Mark S. Levine,
SVP,General Counsel & Sec. -
Michele Ollier,
Director -
Venture Associates Iii Ltd ...,
-
Nico Vandervelpen,
Director -
Rubertis Francesco De,
Director -
Richard E. Russell,
President -
& Johnson Johnson & Johnson...,
-
Capital Iii Llc Care Capita...,
-
Coelho Rogerio Vivaldi,
President and CEO -
Lorenzo Pellegrini,
Director -
Geoff Race,
President -
Plc Barclays,
10% owner